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Purpose: Vein grafts undergo morphologic and functional changes after insertion into the 
arterial circulation with the development of intimal hyperplasia, as well as significant 
alterations in endothelial and smooth muscle cell physiologic responses. 
Methods: Forty New Zealand white rabbits underwent jugular vein interposition grafting 
of  the common carotid artery. Ten animals were controls, 10 animals received 2.25% 
L-arginine supplementation in their drinking water (200 ml/day; 2 gm/kg) 7 days before 
surgery and continued thereafter until harvest, in 10 animals the veins were immersed in 
deferoxamine manganese (DFMn; 10 -a mol/L in heparinized Ringer's lactate for 15 
minutes) before implantation, and 10 received both L-arginine supplementation and 
DFMn therapy. Twenty-eight days after the operation, the vein grafts were harvested for 
either histologic (n = 6) or isometric tension studies (n --- 4). The function of  vein grafts 
was compared with that of  jugular veins. 
Results: Treatment with DFMn, L-arginine, and DFMn/L-arginine produced ecreases in 
mean intimal thickness of 39% (51 + 7 Izm;p < 0.05), 51% (41 -+ 7 j,m;p < 0.05), and 
65% (29 -+ 6 I~m; p < 0.01), respectively, compared with control vein grafts (83 + 12 
I,m). Compared with the control group, the intimal ratio ([intima]/[intima + media]) 
decreased by 16% (difference not significant), 8% (difference not significant), and 47% 
(p < 0.01) in the DFMn-, L-arginine- and DFMn/L-arginine-treated vein grafts, 
respectively. Jugular veins relaxed to acetylcholine (53% + 12% maximal relaxation), 
whereas control vein grafts did not relax. In contrast, vein grafts from each of the 
experimental groups relaxed to acetylcholine with maximal relaxations of 26% -+ 7% 
(p < 0.05 compared with the jugular vein), 22% + 8% (p < 0.05), and 44% + 14% 
(difference not significant) in the DFMn, L-arginine, and DFMn/L-arginine groups, 
respectively. Neither DFMn nor L-arginine had a significant effect on the alterations in 
smooth muscle cell contractility that occur in control vein grafts. 
Conclusion: This study demonstrates that an agent hat modulates free radical production 
combined with a precursor of  nitric oxide formation will lead to a significant decrease in 
the formation of  intimal hyperplasia in arterial vein grafts with the preservation of 
endothelial-derived relaxation. (J VAsc SuRe. 1996;23:410-20.) 
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Presently the most widely used conduit in both 
coronary and peripheral bypass urgery is autologous 
vein. 1,2 All vein bypass grafts undergo morphologic 
and functional changes after insertion into the arterial 
Reprint requests: Per-Otto Hagen, PhD, Duke University Medical 
Center, PO Box 3473, Durham, NC 27710. 
Copyright 9 1996 by The Society for Vascular Surgery and 
International Society fbr Cardiovascular Surgery, North Ameri- 
can Chapter. 
0741-5214/96/$5.00 + 0 2411/67843 
JOURNAL OF VASCULAR SURGERY 
Volume 23, Number 3 Davies et al. 411 
circulation with the development of intimal hyper- 
plasia, which is now a major obstacle to vein graft 
patency. 3,4 Intimal hyperplasia can produce focal 
stenosis in a vein graft within 2 years of insertion and 
can lead to the formation of accelerated atheroscle- 
rotic lesions in the long term. sThere is evidence from 
both humaa~ and animal studies to show that vein 
bypass grafts are not inert but retain considerable 
endothelial and smooth muscle cell function that is 
different from that of ungrafted veins, a These physi- 
ologic changes reflect he particular endothelial and 
smooth muscle cell phenowpes present in the intimal 
hyperplastic vessels. 3 
Controlling the development of intimal hyper- 
plasia is now considered a key to maintaining vein 
graft patency. 3'4 However, in addition, it may also be 
important o modulate the endothelial and smooth 
muscle ceil phenotypes that develop. In this respect, 
many pharmacologic agents that have been successful 
in reducing the development ofintimal hyperplasia n
animal models have also been shown to affect the 
smooth muscle cell contractile phenotype, as reflected 
by changes in vein graft vasomotor function. Capto- 
pril, an angiotensin-converting enzyme inhibitor, 6
and U73489G, a 21-aminosteroid antioxidant, 7 have 
no effect on vein graft contractility, but ketanserin, a 
serotonin (5-hydroxytryptamine) r ceptor antago- 
nist, induces a significant increase in contractility, s 
On the other hand, verapamil, a calcium channel 
antagonist, preserves a contractile profile in the vein 
graft similar to that of nongratted veinsY Alterations 
in endothelial cell phenotypes as evidenced by 
reestablishment of completely intact endothelium- 
dependent relaxation in a vein bypass graft have not 
been reported with these compounds. 
Surgical techniques of vein grafting have been 
refined to such an extent that the structure and 
function of both endothelial nd smooth muscle cells 
can be preserved up to the time of insertion, m 
However, the processes that lead to intimal hyper- 
plasia and the changes in endothelial and smooth 
muscle cell phenotypes begin early after grafting into 
the arterial circulation, a Interventions designed to 
control these lesions should theretbre, if possible, be 
instigated betbre or at the time of vein grafting. In 
this respect, we have recently demonstrated that 
single ex vivo immersion of a vein graft into a 
solution of deferoxamine manganese (DFMn) for 45 
minutes produced a 50% reduction in the develop- 
ment of vein graft intimal hyperplasia. H Further- 
more, there is evidence to suggest that augmentation 
of nitric oxide production in vein grafts by supple- 
mentation with t-arginine (2 gm/kg) can both 
improve endothelial-dependent relaxation (50% of 
jugular vein's response) and significantly decrease 
intimal hyperplasia nexperimental vein grafts.12 This 
study examines the effect in experimental vein grafts 
of the combination of ex vivo deferoxamine manga- 
nese treatment of a vein befbre insertion as a graft and 
systemic >-arginine supplementation started in the 
preoperative period, on the early development of 
intimal hyperplasia and its associated endothelial nd 
smooth muscle cell physiologic hanges. 
~TERIAL  AND METHODS 
Forty New Zealand white rabbits weighing 2.0 to 
2.5 kg underwent right common carotid artery 
bypass grafting with the ipsilateral external jugular 
vein. Ten animals were controls, 10 animals received 
2.25% >-arginine supplementation in their drinking 
water (200 ml/day [2 gm/kg] c-arginine; Sigma 
Chemical Co., St. Louis, Mo.) 7 days before surgery 
and continued thereafter until harvest, in 10 animals 
the veins were immersed in DFMn (10 -3 mol/L in 
heparinized Ringer's lactate for 15 minutes) before 
implantation, and 10 received both c-arginine 
supplementation a d DFMn therapy. Unmanipu- 
lated jugular veins from four animals served as 
controls for the isometric tension studies. All animals 
were killed with an overdose of barbiturates 28 days 
after the operation, and the arterial vein bypass grafts 
were harvested fbr either morphologic or isometric 
tension studies. The arterial pressure of all animals 
was measured at harvest through a cannula placed in 
the middle ear artery with a pressure transducer 
(Viggo Spectramed, Oxnard, Calif.) connected to a 
Mennen Patient Monitor (MR1300; Mennen Medi- 
cal Inc., Clarence, N.Y.). Blood was obtained at the 
time of operation and at harvest; plasma was isolated 
and stored at - 80 ~ C. Arginine concentrations were 
measured by reverse-phase high-pressure liquid chro- 
matography (model 1090L DR5 with HP3392A 
integrator; Hypersiel ODS C18, 200 mm • 4.6 mm 
column; injection volume 5 ~1; Hewlett-Packard 
Co., Andover, Mass.). Animal care complied with the 
"Principles of Laboratory Animal Care" as fbrmu- 
lated by the National Society tbr Medical Research 
and the "Guide for the Care and Use of Laboratory 
Animals" issued by the National Institutes of Health 
(U.S. Department of Health and Human Services, 
National Institutes of Health publication No. 80-23, 
revised 1985). 
Operative procedures. Anesthesia was induced 
and maintained with subcutaneously injected keta- 
mine hydrochloride (60 mg/kg, Ketaset; Bristol 
Laboratories, Syracuse, N.Y.) and xylazine (6 mg/kg, 
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Anased; Llyod Laboratories, Shenandoah, Iowa). 
Antibiotic prophylaxis with 30,000 IU/kg penicillin 
benzathine and procaine penicillin (Durapen; Vedco 
Inc., Overland Park, Kan.) was given intramuscularly 
at the time of induction. Surgery was performed with 
an operating microscope (JKH 1402; Edward Weck 
Inc., Research Triangle Park, N.C.) under sterile 
conditions. After exposure through a midline longi- 
tudinal neck incision, the right external jugular vein 
was identified, its branches were cauterized at a 
distance from the vein to minimize injury, and it was 
dissected out. After excision, the vein was immersed 
in a heparinized Ringer's lactate solution at room 
temperature and without distension (5 IU/ml, 
heparin; Elkins-Sinn Inc., Cherry Hill, N.J.) for 
approximately 15 minutes while the right common 
carotid artery was identified and dissected and both 
proximal and distal control was obtained. Heparin 
(200 IU/kg) was administered intravenously. A
proximal longitudinal arteriotomy was made and one 
end of the reversed jugular vein was anastomosed to 
the artery in an end-to-side manner with continuous 
10-0 microvascular monofilament nylon suture 
(Ethilon; Ethicon Inc., Somerville, N.J.). The distal 
anastomosis was performed in a similar manner. 
Throughout the procedure, care was taken to avoid 
unnecessary instrumentation f the vein graft. The 
right common carotid artery was ligated and divided 
between the two anastomoses with 4-0 silk sutures 
and the wound was closed in layers. 
Morphologic studies. After isolation and hep- 
arinization (200 IU/kg, intravenously), six control 
and six experimental vein grafts from each group 
were perfusion fixed in situ at 80 mm Hg with an 
initial infusion of Hanks balanced salt solution 
(Gibco Laboratories, Life Technologies Inc., Grand 
Island, N.Y.) followed by 2% glutaraldehyde made 
up in 0.1 mol/L cacodylate buffer (pH 7.2) supple- 
mented with 0.1 mol/L sucrose to give an osmolality 
of approximately 300 mOsm. After 60 minutes, the 
specimen was removed, immersed in the glutaralde- 
hyde fixative for an additional 24 hours, and then 
processed for light microscopy. After immersion in 
the fixative for 48 hours, the graft was divided into a 
proximal, middle, and distal third, and cross-sections 
from the midpart of each third were taken for 
processing. Following standard procedures, the 
specimens were stained with a modified Masson's 
trichrome and Verhoeffs elastin stain. The lumen, 
intima, and media were defined and their dimensions 
(area and thickness) calculated by videomorphom- 
etry (Innovision 150; American Innovision Inc., San 
Diego, Calif.). The intima and media were delineated 
by identification of the demarcation between the 
criss-cross orientation of the intimal hyperplastic 
smooth muscle cells and circular smooth muscle cells 
of the media, and the outer limit of the media was 
defined by the interface between the circular smooth 
muscle cells of the media and the connective tissue of 
the adventitia. For scanning electron microscopy, 
midportion specimens of glutaraldehyde-fixed grafts 
were rinsed with the same buffer solution as de- 
scribed above, dehydrated in ascending concentra- 
tions of ethanol, transferred to acetone as an inter- 
mediate fluid, critical point dried from CO2, 
mounted on specimen stubs, and sputter coated with 
gold-palladium according to standard techniques. All 
specimens were examined in a Philips 500 scanning 
electron microscope (N.V. Philips, Eindhoven, The 
Netherlands) at an accelerating voltage of 12 or 20 
kV. For transmission electron microscopy, represen- 
tative sections from the midportion of the 
glutaraldehyde-fixed grafts were post-fixed for 1 hour 
at room temperature in 1% osmium-tetroxide is- 
solved in the same cacodylate buffer as that used for 
the glutaraldehyde solution. After dehydration in 
ascending concentrations of ethanol, the specimens 
were embedded in Epon 812 monomer. Polymer- 
ization was carried out overnight at 40 ~ C followed 
by 2 days at 60 ~ C. Ultrathin sections were cut with 
a diamond knife on a Reichart ultramicrotome 
(Reichart Optische Werke AG, Vienna, Austria), 
contrasted with uranyl acetate and lead citrate, and 
examined in a Philips 300 transmission electron 
microscope (N.V. Philips) operated at 40 kV. 
Functional studies. For isometric tension stud- 
ies, vessels (four jugular veins and four vein grafts 
from both the control and experimental groups) were 
sectioned in situ into 5 mm segments and excised and 
each ring was immediately mounted between two 
stainless-steel hooks in 5 ml organ baths containing 
oxygenated Krebs solution (122 mmol/L NaCI, 4.7 
mmol/L KCI, 1.2 mmol/L MgCI2, 2.5 mmol/L 
CaCl2, 15.4 mmol/L NaHCO3, 1.2 mmol/L 
KH2PO4, and 5.5 mmol/L glucose, maintained at 
37 ~ C and oxygenated with 95% 0 2 and 5% CO2). 
One hook was fixed to the bottom of the bath and the 
other was connected to a force transducer (Myograph 
F-60; Narco Bio-Systems, Houston, Texas). The 
isometric responses of the tissue were recorded on a 
multichannel polygraph (Physiograph Mk111-S; 
Narco Bio-Systems). The tissues were then placed 
under 0.5 gm tension and allowed to equilibrate in 
Krebs solution for 1 hour. During the equilibration 
period, the Krebs solution was replaced every 15 
minutes. After equilibration, the resting tension was 
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Fig. 1. A, Mean intimal and medial thicknesses of control graft, DFMn-treatcd vein graft, 
i-argininc-treated vcm graft, and DFMn/L-arginine-trcatcd vein graft. There are significant 
reductions in intimal thicknesses of all experimental grafts compared with control group 
(p < 0.0001 by Kruskal-Wallis nonparametric analysis of variance; *p < 0.05 and ~ "p < 0.01 
by a post hoc Dunn's multiple-comparison test. There wcrc no significant changes in thickness 
oi media (p = 0.16). B, Composite photomicrograph of cross section of wall of control vein 
graft (A), DFMn-treated vein graft (B), i_-arginine-treated vein graft vein graft (C), and 
DFMn/L-arginine-trcated vein graft (D). Aln'on,s indicate demarcation between intimal 
hyperplasia (H) and media (M). (Original magnification x 25{).) 
adjusted in increments from 0.5 to 2.5 gm and the 
maximal response to a modified oxygenated Krebs 
solution (60 mmol/L KC1, 66.7 mmol/L NaC1, 1.2 
mmol/L MgCI2, 2.5 mmol/L CaCI2, 15.4 mmol/L 
NaHCO3, 1.2 mmol/L KH2PO4, and 5.5 mmol/L 
glucose) was measured to establish a length-tension 
relationship. The tension at which a ring generated its 
maximal contractile response to the modified Krebs 
solution was considered the optimal resting tension 
l~br that particular ing, and the ring was set at this 
tension for subsequent studies. Cumulative dose- 
response curves to norepinephrine (10 -9 tO 10 -4 
tool/L), serotonin (10 9 to 10 -4 mol/L), bradyldnin 
(10 -9 to 10 -s mol/L), and histamine (10 8to 10 3 
tool/L) were peribrmed. After precontraction with 
prostaglandin F2~ (10 5 tool/L), rel;Lxation in re- 
sponse to acetvlcholine (10 8 to 10 -4 mol/L), 
serotonin (10 ')'to 10 4 tool/L), calcimn ionophore 
(A23187; 10 s to 10 4 mol/I,), and soditnn nitro- 
prusside (10 -8 to 10 4 mol/L) was determined. The 
tissue was allowed to reequilibrate for a mininmnl of 
30 minutes between each experimental run. All drugs 
were obtained from Sigma Chemical Co. (St. Louis, 
MoO. 
Data and statistical analysis. The isometric 
responses of the rings were converted to percent 
maximal response and plotted against he negative 
logarithm of the agonist dose to produce dose- 
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Fig. 2. Scanning electron micrograph of luminal surfaces of control (A), c-arginine-treated 
(B), DFMn-treated (C), and DFMn/L-arginine-treated (D) vein grafts. Vascular surface of v in 
grafts is covered by continuous layer of endothelial cells (EC) with minimal differences b tween 
groups. Cell borders are shown bvarrows and microvilli by white dots. (S, Stomata; D, dimples.) 
Table I. Dimensional analysis 
Control DFMn ~-Arainine DFMn with >arainine p 
Luminal area (mm 2) 14.8 +_ 2.2 14.7 + 2.5 35.8 + 4.1" 13.8 -+ 2.5 0.014 
Intimal area (ram 2) 1.02 _+ 0.14 0.73 _+ 0.15 0.95 +_ 0.13 0.39 • 0.09i- 0.006 
Medial area (mm 2) 1.04 +- 0.10 0.88 + 0.14 1.11 -+ 0.25 1.11 • 0.08 0.26 
Intimal ratio 0.49 -+ 0.03 0.41 • 0.03 0.45 -+ 0.03 0.26 -+ 0.06t 0.007 
Luminal index 29.6 +- 3.1 36.2 + 2.5 38.8 + 2.6 38.1 -+ 3.5 0.I1 
The dimensions of the lumen, intima, and media of the control vein grafts and DFMn-, L-arginine-, and DFMn with L-arginine-treated 
vein grafts to both contractile and relaxing agonists are given. Values are expressed as means + SEM. Statistical comparisons are bv 
Kruskal-Wallis nonparametric analysis of variance with post hoc Dunn's multiple-comparisons test. 
*p < 0.05 compared with e control vein graft. 
tp < 0.01 compared with e control vein graft. 
response curves. The ECs0 value (the concentration 
for the half-maximal response) for contraction or 
relaxation of each ring was calculated by logistic 
analysis and is expressed as the pD 2 defined as 
logl0[ECs0]) a The actual maximal contractile re- 
sponse to each agonist was expressed in milligrams of 
force generated and is then standardized to the 
contractile ratio (contractile ratio = actual maximal 
contraction to an agonist/actual maximal contraction 
to 60 mmol/L KCI). Functional data are presented as 
the mean _+ SEM and groups were compared by 
analysis of variance with post hoc Tukey-Kramer 
multiple-comparison tests, where appropriate. After 
determination of dimensions of each vein graft, a 
ratio of the intimal and medial areas (intimal 
ratio = intimal area/[intimal + medial areas]) and a 
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Fig. 3. Transmission electron micrograph of cross section through wall of control (A), 
L-arginine-treated (B), DFMn-treated (C), and DFMn/L-arginine-treated (D) vein grafts. Vein 
grafts have well-defined en othelial cells (EC) with convex surface profile. Intimal hyperplasia 
contains numerous layers of smooth muscle cells of various phenoFpes (synthetic [SMCI], 
intermediate [SMCfl, and contractile [SMCfl) embedded in matrix of connective tissue 
(asterisks). There are minor qualitative differences between each group. Microvilli on endothelial 
cells are indicated by arrowheads and cytoplasmic vacuoles by V. 
luminal diameter to cross-sectional wall thickness 
(luminal index = luminal diameter/[cross-sectional 
wall thickness]) were calculated. Morphologic data 
are expressed as the mean + SEM, and statistical 
differences between these groups of  data were tested 
with a Kruskal-Wallis nonpararnetric analysis of 
variance with post hoc Dunn's multiple-comparison 
tests, where appropriate. A p value <0.05 was 
regarded as significant, 
RESULTS 
All animals urvived to harvest, and all grafts were 
patent at harvest. There were no significant differ- 
ences in mean arterial pressure between the four 
groups. Plasma arginine concentrations increased 
approximately twofold to 340 +__ 34 pmol/L at the 
time of operation and 289 + 24 pmol/L at harvest in 
the treated animals compared with the control 
animals (185 -+ 19 pmol/L). 
Morphology 
All groups of vein grafts had similar macroscopic 
appearances atharvest. The control vein grafts had a 
greater degree of intimal hyperplasia than the 
DFMn-, L-arginine-, or DFMn/L-arginine-treated 
vein grafts by light microscopy. The histologic 
features of the lesion in both the control and 
experimental groups were similar (Fig. 1). The 
smooth muscle cells in the intima were arranged in a 
randomly orientated pattern within a connective 
tissue matrix. The media of the control and DFMn 
grafts were histologically similar in size and appear- 
ance (Fig. 1). In contrast, there was a decrease in the 
thickness of the media of the L-arginine- and 
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Fig. 4. Dose-response curve to acetylcholine (A), serotonin (B), calcium ionophore (C), and 
sodium nitroprusside (D) in prostaglandin F2~ precontracted jugular vein (o), control vein graft 
(.), DFMn-treated vein grafts ([]), L-arginine treated vein grafts ("), and DFMn/L- 
arginine-treated vein grafts (A). Values are means +_ SEM percent precontracted tension. 
DFMn/L-arginine-treated vein grafts; however, this 
did not reach significance (Fig. 1). In the middle 
segments (Fig. 1), treatment with DFMn, L-arginine, 
and DFMn/L-arginine produced ecreases in mean 
intimal thickness of 39% (51 +_ 7 ~m; p < 0.05), 
51% (41+ 7 ~tm; p < 0.05), and 65% (29_+ 
6/~m; p < 0.01), respectively, compared with con- 
trol vein grafts (83 _+ 12 ~m). Only the L-arginine- 
treated vein grafts howed asignificant increase in the 
overall luminal areas of the treated vein grafts 
compared with controls (Table I). The cause of this 
has not been defined, but when this result was 
standardized through the luminal index the aberation 
was nullified. Compared with the control group, the 
intimal ratio decreased by 16% (difference not 
significant), 8% (difference not significant), and 47% 
(p < 0.01) in the DFMn-, L-arginine-, and 
DFMn/L-arginine-treated vein grafts, respectively 
(Table I). The three treatment groups had luminal 
indexes 22% to 31% higher than the control group; 
however, this did reach significance (Table I). 
In scanning and transmission electron micros- 
copy, the vascular surfaces of the vein grafts from the 
control and three experimental groups were covered 
with a continuous layer of endothelial cells without 
any attached polymorphonucleocytes or platelets 
(Figs. 2 and 3). The endothelial cells in each of the 
experimental groups frequently appeared to be 
thicker and longer than their counterparts in the 
control vein grafts. Vein grafts in both the control 
and experimental groups appear to contain several 
phenotypes of smooth muscle cells (i.e., cells in 
various stages of differentiation). These smooth 
muscle cells can be phenotypically defined on an 
ultrastructural basis as synthetic, intermediate, or 
contractile. In the synthetic cell type, the cytoplasm of 
the smooth muscle cells was filled with synthetic 
organelles. In the intermediate c ll type, the smooth 
muscle cells contained a core of synthetic organelles 
with a thick peripheral ayer of well-developed 
myofilaments. The cytoplasm of the smooth muscle 
cells from the contractile cell type was filled predomi- 
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nantly with contractile filaments. The respective 
proportions of these phenotypes were not quanti- 
rated further or their phcnotypes characterized fur- 
ther. In contrast o the control vein graft, the vein 
grafts in the experimental groups have a marked 
reduction in formation of intimal hyperplasia. Com- 
mon to all of these groups of experimental vein grafts 
was the abundance of synthetic and intermediate 
smooth muscle phenotypes within the vessel wall. 
Physiologic responses 
Relaxation. Jugular veins relaxed to acetylcho- 
line (receptor mediated, endothelium dependent) 
with a maximal response of 53% -+ 12%, whereas 
control vein grafts did not relax to this agonist (Fig. 
4,A). In contrast, vein grafts from each of the experi- 
mental groups relaxed to acetTlcholine with maximal 
relaxations of 26% _+ 7% (p < 0.05 compared with 
the jugular vein), 22% _+ 8% (p < 0.05 compared 
with the jugular vein), and 44% + 14% (difference 
not significant compared with the jugular vein) in the 
DFMn, L-arginine,and DFMn/L-arginine groups, re- 
spectively (Table II). The jugular vein (76% +_ 7%) 
and vein grafts from the DFMn-treated 
(17% _+ 31%;p < 0.05 compared with the jugular 
vein), L-arginine-treated (23% _+ 15%; p < 0.05 
compared with the jugular vein), and DFMn/L- 
arginine-treated (21% + 17%;p < 0.05 compared 
with the jugular vein) groups rclaxed to serotonin 
(receptor mediated, endothelium dependent relax- 
ation), whereas those vein grafts in the control group 
did not (Table II; Fig. 4, B). In response to calcium 
ionophore (receptor-independent, endothelial- 
dependent relaxation), all vein grafts relaxed with 
responses of 154% -_ 36%, 262% -+ 60%, and 
107% +-17% for the DFMn, L-arginine, and 
DFMn/L-arginine groups, respectively (Table II; Fig. 
4, C). The maximal response to calcium ionophore in 
the jugular vein was 114% + 19% (Table II). Non- 
endothelium-dependent relaxations in response to 
sodium nitroprusside were increased significantly in 
'all vein grafts compared with the jugular veins 
(88% + 10%; p = 0.04); there were no differences 
in the responses of the vein grafts between the 
control (199% _+ 19%) and experimental groups 
(180% _+ 44%, 229% _+ 40%, and 237% -+ 44% 
in the DFMn, c-arginine, and DFMn/L-arginine 
groups, respectively; Table II; Fig. 4, D). 
Contraction. The maximal contractions gen- 
erated in response to potassium chloride (60 
mmol/L) in all three of four vein grafts (control: 
300 -+ 33 mg; DFMn: 248 _+ 52 mg; L-arginine: 
254 _+ 38 mg) were significantly greater than those 
in the jugular veins (150 _+ 20 mg; p < 0.02). 
There was no significant difference between the 
control and DFMn/~,-arginine (182 _+ 17 mg) 
groups. There was no difference in the sensitivity. 
of the norepinephrine r sponses of the jugular veins 
and the vein grafts from the control and experi- 
mental groups (Table II). The maximal response to 
norepinephrine was augmented in the control, 
L-arginine, and DFMn/L-arginine groups compared 
with either the jugular vein or the DFMn-treated 
vein grafts (Table III). Although the jugular veins 
do not contract o serotonin, vein grafts from the 
control and experimental groups responded to se- 
rotonin with equivalent maximal responses (Table 
III); there was a marginally significant increase in 
the sensitivity of the scrotonin response in the 
c-arginine and DFMn/c-arginine groups compared 
with the control and DFMn groups (Table II). The 
sensitivity to histamine (p = 0.0003) and brady- 
kinin (p = 0.0001) was reduced significantly in the 
control and experimental vein grafts compared with 
the jugular veins (Table II). Maximal responses to 
both histamine and bradykinin were decreased, 
compared with the jugular vein, in vein grafts from 
both the control and experimental groups Table 
III). 
DISCUSSION 
Both activated oxygen species and nitric oxide are 
free radicals produced by mammalian cells, 14 and 
there appears to be a homeostatic balance between 
these two free radical groups in vivo, particularly 
within the endothelial cell. 14 Nitric oxide can decrease 
free radical-mediated inju~, and inhibition of free 
radical production can augment nitric oxide -medi- 
ated responses) ,16 This study has shown that regi- 
mens to both decrease oxygen free radical availability. 
and augment nitric oxide production can significantly 
reduce the development of intimal hyperplasia nd 
preserve ndothelial-dependent relaxation in experi- 
mental vein grafts. Furthermore, the combination of 
DFMn and L-arginine has an additive effect on 
controlling the development of intimal hyperplasia 
and restores endothelial-dependent r laxation of vein 
grafts to that of a nongrafted jugular vein. However, 
neither treatment has a significant effect on the 
alterations in smooth muscle cell contractility, pro- 
duced by grafting the vein into the arterial circulation 
even though the volume of smooth muscle cells in the 
treated grafts is reduced. 
Several studies have shown that there is a time- 
dependent accumulation and infiltration of polymor- 
phonuclear neutrophils into the wall of a vein graft, 
JOURNAL OF VASCULAR SURGERY 
418 Davies et al. March 1996 
Table II. Sensitivity 
Vein grafts (%) 
Jugular vein (%) Control DFMn i,-Arginine DFMn with L-arainine p 
Contraction 
Norepinephrine 5.82 • 0.31 6.08 + 0.o9 6.43 • 0.21 6.46 _+ 0.19 5.91 • 0.16 0.065 
Serotonin No response 6.20 • 0.15 6.42 +- 0.09 6.62 + 0.12 6.63 -+ 0.09 0.05 
Bradykinin 6.95 • 0.19 5.73 -+ 0.38 * 4.99 + 0.21~- 6.02 • 0.185 5.87 • 0.17~: 0.0001 
Histamine 5.80 -+ 0.09 5.07 + 0.13 ~ 4.91 • 0.01 ~ 5.10 • 0.22~ 4.96 • 0.21 ~ 0.0003 
Relaxation 
Acetylcholine 6.84 -+ 0.37 No response 6.42 + 0.15 6.21 • 0.25 6.32 • 0.15 0.31 
Serotonin 6.98 • 0.20 No response 6.57 • 0.51 6.46 -+ 0.19 5.91 • 0.16 0.12 
Calcium ino- 6.88 • 0.20 6.05 • 0.64 6.27 • 0.12 6.73 -+ 0.21 5.73 • 0.18 0.12 
phore 
Sodium nitro- 5.97 -+ 0.19 5.34 -+ 0.22 6.24 + 0.085 6.21 -+ 0.155 5.68 • 0.14 0.01 
prusside 
Sensitivity. of the jugular veins, control vein grafts, and DFMn-, >-argininc-, and DFMn with t,-arginine-treated vein grafts to both 
contractile and relaxing agonists is shown. Values arc pD 2 defined as - logm[ECs0 ] and are expressed as means • SEM. Statistical 
comparisons are by analysis of variance with post hoc Tukey's comparison test. 
~p < 0.01 compared with the jugular vein. 
~-p < 0.001 compared with the jugular vein. 
Sp < 0.05 compared with the jugular vein. 
Table III. Maximal contractile responses 
Vein grafts 
Contraction Jugular vein Control DFMn t,-Arginine DFMn with i,-arginine p 
Norepinephrine 0.87 -+- 0.19 1.62 • 0.37 ~ 0.91 • 0.13t 1.66 + 0.33 ~ 1.41 -+ 0.18t 0.0001 
Serotonin$ No rcsponse 0.41 • 0.27 0.39 + 0.26 0.50 • 0.06 0.71 • 0.06 0.15 
Bradvkinin 2.98 -+ 0.65 0.38 • 0.21 ~ 0.61 • 0.11 * 0.56 • 0.13 ~ 1.12 "- 0.18 ~ 0.0001 
Histamine 2.66 • 0.08 1.69 • 0.47 0.07 • 0.05 ~ 0.57 • 0.17 ~ 0.71 • 0.06" 0.0001 
The standardized maximal contractile responses to norepinephrine, serotonin, bradykinin, and histamine in jugular veins, control vein 
grafts, the DFMu-treated vein grafts, the L-arginine-treated vein grafts, and the DFMn/l.-arginine-treated vein grafts are shown. Values 
are the means • SEM of the contractile ratio, where contractile ratio = actual maximal contraction to an agonist/actual maximal 
contraction to 60 mmol/L KCI. 
*p < 0.01 compared with the jugular vein by analysis of variance with post hoc Tukey-Kramer multiple-comparison tests. 
~-p < 0.05 compared with the jugular vein by analysis of variance with post hoc Tukey-Kramer multiple-comparison tests. 
~cStatistical nalysis excludes the jugular vein. 
suggesting that there may be considerable polymor- 
phonuclear neutrophil-mediated free radical injury 
to both the endothelial nd smooth muscle cells, a'17'18 
Activated oxygen species can induce smooth muscle 
proliferation and proto-oncogene expression i  vitro 
and thus may be important in the initiation of intimal 
hyperplasia. 19In addition, polymorphonuclear neu- 
trophils have been shown to stimulate smooth muscle 
cell proliferation i  vitro, TM and a variety of inflamma- 
tory mediators are known to act as smooth muscle 
mitogens. ~8,21 The probable importance of oxygen 
free radicals in the development of intimal hyperpla- 
sia has been demonstrated by the facts that single 
therapy of vein grafts with DFMn by immersion for 
45 minutes before insertion can reduce intimal hyper- 
plasia by 50%, 11 whereas chronic therapy with the 
antioxidant 21-aminosteroid (U74389G) also ap- 
peared to be as effective in controlling the develop- 
ment of intimal hyperplasia. 7 The benefit of DFMn 
may derive from its ability to provide transient pro- 
tection of the venous tissue during reperfusion i  the 
arterial circulation until the intrinsic cellular antioxi- 
dant system accommodates to the new environ- 
ment. 22 The previous data on DFMn in vein grafts 
used a 4S-minute immersion time, 1~ whereas in this 
study immersion in DFMn was for only 15 minutes 
and resulted in a significant decrease in intimal hyper- 
plasia in the vein grafts associated with a small but 
notable preservation of endothelial-derived relax- 
ation. The apparent decrease in the efficacy between 
the previous report on DFMn (50%) and this result 
(39%) may be due to the use of Ringer's lactate 
instead of normal saline solution in the storage solu- 
tion for the vein grafts. This change in storage solu- 
tion has now been shown to influence the develop- 
ment of intimal hyperplasia positively at 28 days. 2a 
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The relationship of endothelial cell structure and 
function with the development ofintimal hyperplasia 
is well recognized.24"25 Loss of nitric oxide-mediated 
relaxation caused by the physical loss of the endothe- 
lial lining or the dystunction of the endothelial cells is 
characteristic of intimal hyperplastic lesions. Produc- 
tion of nitric oxide can inhibit platelet aggregation 
and inhibit polymorphonuclear neutrophil adhe- 
sion, function, and chemotaxis. 26Furthermore, ni- 
tric oxide can inhibit smooth muscle cell growth 
directly. 26-2s Nitric oxide is synthesized from the 
conversion of ~,-arginine to citrulline by a family of 
nitric oxide synthases that are either a membrane- 
bound constitutive isozyme or a cytosolic-inducible 
isozyme. A recent study has demonstrated that short- 
term oral >-arginine supplementation preserves nitric 
oxide-mcdiated relaxation with a significant reduc- 
tion in the development ofintimal hyperplasia n vein 
grafts. 12 It does not, however, prevent he altered 
smooth muscle cell contractility induced by vein 
grafting. In addition to this improved endothelial cell 
function, L-arginine therapy may also have inhibited 
platelet or polymorphonuclear neutrophil-mediated 
stimulation of the intimal hyperplastic response 
through increased nitric oxide production. 26 
In this study, the degree of intimal hyperplasia 
was reduced by 65% by the combination of DFMn 
and L-arginine. This decrease may represent he 
maximal degree of inhibition that can be achieved 
pharmacologically, given the premise that the vein 
graft nmst undergo a degree of"arterialization" as it 
adapts to the increased hemodynamic forces placed 
on it by the arterial circulation. 29,3~ Another novel 
finding is that the receptor-mediated endothelium- 
dependent relaxation ismaintained at the same levels 
as that of the unoperated jugular veins, indicating the 
preservation of a venous endothelial cell phenotype. 
Serotonin-mediated relaxation remained blunted in 
all experimental groups compared with the unoper- 
ated jugular veins. Serotonin-induced relaxation ap- 
pears to be endothelium dependent and nitric oxide 
mediated, 3~ so the persistently impaired responses in 
the vein grafts may reflect the combination of 
contractile and relaxing responses of the vein graft 
smooth muscle and endothelial cells. The responses 
to calcium ionophore, a receptor-independent, 
endothelium-dependent mediator were similar in all 
the grafts with the exception of the c-arginine group, 
which was both more sensitive and had a greater 
maximal response to this agonist than any other 
group. Calcium ionophore stimulates nitric oxide 
release from the endothelial cells independently of 
receptor mechanisms by increasing intracellular con- 
centrations of Ca 2 ~. The result suggests that the 
intrinsic abiliw of the endothelial cells in the vein 
graft to produce nitric oxide remains intact, but its 
activation system is impaired. Similarly, the re- 
sponses to sodium nitroprusside were unchanged 
with the exception that the sensitivities to the agonist 
in the ,,-arginine and DFMn groups were increased. 
Sodium nitroprusside is a direct smooth muscle cell 
relaxant acting through the activation of cellular- 
soluble guanylate cyclase. 26 Overall, these results 
suggest that the nonreceptor activation of cndo- 
thelium-dependent relaxation and the guanylate cy- 
case mechanism in the smooth muscle cells is intact in 
both the control and treated vein grafts. 
In conclusion, this study has demonstrated that 
agents that modulate free radical concentrations and 
augmentation of the synthesis of nitric oxide in 
arterial vein grafts lead to a decrease in the tbrmation 
of intimal hyperplasia in vein grafts, and this is 
associated with the complete preservation of 
endothelial-derived relaxation. Because of the non- 
toxic properties of both compounds, strong consid- 
erations hould be given to conducting a clinical trial 
of this therapeutic regimen. 
The technical assistance of Ms. Lizzie Barber (Duke 
Universi~9 is greatly apprcciatcd. Microsumres were a gift 
from Ethicon Inc., Somerville, N.J., and DFMn was a gilt 
from Dr. Irwin Fridovich. 
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